European journal of hospital pharmacy : science and practice最新文献

{"title":"Drug repositioning in Alzheimer's disease: a vascular perspective targeting the NO-cGMP pathway.","authors":"Sandra Caíña López, Andrea Portela Sotelo, Silvia Vázquez-Gómez","doi":"10.1136/ejhpharm-2026-005089","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005089","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medicinal mushrooms and chemotherapy: therapeutic synergy or hidden risk?","authors":"Aron Misa Garcia, Sara Ferro Rodríguez","doi":"10.1136/ejhpharm-2026-005096","DOIUrl":"https://doi.org/10.1136/ejhpharm-2026-005096","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colchicine-enzalutamide interaction: clinical implications and multi-disciplinary management.","authors":"Ana Isabel Cachafeiro Pin, Lucía Grandío Leivas, Francisco Caramés Masana, Alicia Folgar Torres, Maria Alejandra Naranjo Sánchez","doi":"10.1136/ejhpharm-2024-004459","DOIUrl":"10.1136/ejhpharm-2024-004459","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"293-294"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication adherence in chronic myeloid leukemia: a hospital pharmacy-level analysis.","authors":"Violeta Getova-Kolarova, Maria Kamusheva, Natalia Kokudeva, Miglena Doneva, Ilko Getov","doi":"10.1136/ejhpharm-2025-004552","DOIUrl":"10.1136/ejhpharm-2025-004552","url":null,"abstract":"<p><strong>Objectives: </strong>The objective was to evaluate medication adherence levels in patients with chronic myeloid leukaemia (CML) and to identify factors that may undermine adherence.</p><p><strong>Methods: </strong>This prospective, cross-sectional study was conducted over a 2-month period among ambulatory patients with CML monitored at one of the country's leading hospitals for diagnosing, treating and monitoring CML in Bulgaria.</p><p><strong>Results: </strong>Among 70 participants, 91.4% showed high medication adherence, with only 1.4% reporting low adherence. No significant differences in adherence between therapy groups (imatinib vs nilotinib, p=0.1830), gender (p=0.0887) or age groups (p=0.8748) were revealed. Education level was associated with adherence, with lower adherence observed in patients with primary education (p<0.0001). Quality of life, measured using utility values (median=0.8770) and visual analogue scale (mean=80), did not significantly differ based on adherence levels, therapy type or education level. Logistic regression showed that men had 1.9 times higher odds of high adherence compared with women (p>0.05). Patients under 65 had 3.3 times higher odds of adherence compared with those over 65 (p>0.05), and those on imatinib had 22.86% of the adherence odds compared with those on nilotinib. The findings suggest that maintaining high medication adherence is crucial for positive therapeutic outcomes in patients with CML.</p><p><strong>Conclusion: </strong>Patients with CML in Bulgaria show high medication adherence, likely contributing to their overall quality of life. These findings emphasise the importance of maintaining adherence for optimal treatment outcomes in CML. Future research should explore the factors influencing adherence in this population and assess the role of hospital pharmacists in supporting medication management.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"244-248"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of potential particulate contamination in intravenous solutions in an adult intensive care unit: a targeted correlation analysis.","authors":"Yvonne Remane, Annett Frisch, Johanna Krainz, Jan Vogel, Donald Ranft, Julia Borella, Vincent-Christoph Klaus, Sirak Petros, Thilo Bertsche","doi":"10.1136/ejhpharm-2025-004523","DOIUrl":"10.1136/ejhpharm-2025-004523","url":null,"abstract":"<p><strong>Background: </strong>Intravenous drug administration is essential in intensive care treatment. However, the risk of particulate contamination in infusion solutions during treatment is often underestimated.</p><p><strong>Methods: </strong>Residual amounts of infusion solutions prepared and administered at the adult intensive care unit were examined for visible and subvisible particles according to the recommendations of the European Pharmacopoeia monographs 2.9.19 and 2.9.20.</p><p><strong>Results: </strong>Samples from 169 infusion solutions were collected, 149 of which could be analysed. The Pharmacopoeia requirements for visible particles were not fulfilled in 42.9% (n=64/149) of the samples, while the requirements for subvisible particles were not met in 4.7% (n=7/149). A specific correlation between the pharmaceutical drugs or within the infusion set (bottle vs connected infusion line) and particulate contamination was not possible as the sample was too small for a correlation analysis. A Spearman rho analysis showed no correlation between particle contamination and administration mode (subvisible (10 µm): p=0.969, r=-0.005; subvisible (25 µm): p=0.834, r=-0.026; visible: p=0.711, r=-0.047) and particle contamination and dosage form (subvisible (10 µm): p=0.291, r=-0.092; subvisible (25 µm): p=0.513, r=0.057; visible: p=0.415, r=0.071).</p><p><strong>Conclusions: </strong>This study showed that residuals of intravenously administered solutions have particulate contaminations. A specific causal factor was not identified.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"260-265"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to manage the overwhelming amount of database-detected interactions? A focus group meeting study on the management of database-detected risks of drug interactions.","authors":"Dénes Kleiner, Faraz Haghverdi, Orsolya Szépe, István László Horváth, Szilvia Sebők, Dezső Csupor, András Horváth, Artúr György Balogh, Katalin Monostory, László Kóbori, Máté Balázs, Magdolna Dank, Csaba Mihály Móczár, Ádám Becze, András Süle, Romána Zelkó","doi":"10.1136/ejhpharm-2025-004478","DOIUrl":"10.1136/ejhpharm-2025-004478","url":null,"abstract":"<p><strong>Objectives: </strong>Database-assisted screening may help detect the risks of drug interactions, but less than 10% of flagged interactions have clinical manifestations, potentially leading to alert fatigue among healthcare providers. To address this issue, this study aimed to develop a concise framework to support the management of database-indicated interaction risks.</p><p><strong>Methods: </strong>A grounded theory approach was used to design, evaluate and develop the framework. Participants included healthcare professionals and laypersons with experience using narrow therapeutic index medications, as well as individuals recommended by them. Two focus group discussions were conducted (N₁=6 and N₂=5), each lasting approximately 2 hours and following the same agenda. In one case, a follow-up one-on-one interview was held because the participant indicated further insights at the end of the session.</p><p><strong>Results: </strong>Participants identified key decision-making questions for the framework, including the evidence base for interacting drugs, severity and documentation level of the interaction, availability of safer alternatives, and the presence of confounding factors. The framework was considered useful and, following refinement, potentially suitable for clinical implementation. A key insight was that integration into healthcare curricula is essential for achieving long-term impact. Overall, the proposed tool may assist in managing interaction risks in diverse clinical scenarios and reduce alert fatigue among healthcare professionals.</p><p><strong>Conclusion: </strong>Although further clinical validation is needed, the framework provides a foundation for improving the management of database-detected drug interactions.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"213-218"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144590728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Maintaining appropriate stocks in an operating room pharmaceutical unit: risk mapping of the supply chain.","authors":"Caroline Figeac, Cordélia Salomez-Ihl, Rémi Toth, Virginie Filisetti, Assia Daikh, Philippe Py, Delphine Schmitt, Pierrick Bedouch","doi":"10.1136/ejhpharm-2025-004588","DOIUrl":"10.1136/ejhpharm-2025-004588","url":null,"abstract":"<p><strong>Objectives: </strong>Supply chain management is a major challenge for hospital pharmacists, particularly in minimising stock-outs and their impact on patient care. This study aimed to map the risks associated with the supply chain of sterile medical devices in the operating room using a patient-centred approach.</p><p><strong>Methods: </strong>Risk analysis, conducted using the 'failure modes and effects analysis' approach, took place in 2024. It focused on the sterile medical devices supply chain within an operating room pharmaceutical unit. A multidisciplinary working group developed a risk map for stock discrepancies in four stages: identification of risks, risk rating based on occurrence and severity, listing of control measures and prioritisation of risks.</p><p><strong>Results: </strong>The risk analysis identified 52 risks across seven subprocesses, with 10% of these risks classified as priority. These priority risks mainly involved the emergency dispensing of equipment in the operating room, the scheduled provision of medical devices through the preparation of case carts, and the storage of products in the pharmaceutical unit. Key areas for improvement included staff training, enhancing software expertise and strengthening quality assurance.</p><p><strong>Conclusions: </strong>This study presents the first risk map of stock errors for health products in a hospital setting. This approach is applicable to other supply chains in healthcare. Effective risk management depends on a collective effort and the engagement of all stakeholders. Optimising stock management is critical in enhancing the quality and safety of care provided to patients.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"249-253"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extravasation of enfortumab vedotin: a case report and literature review on antibody-drug conjugates.","authors":"Stefania Pipitone, Maria Giuseppa Vitale, Cinzia Baldessari, Roberto Sabbatini, Massimo Dominici, Carla Porretta Serapiglia, Lucia Ricchi, Marianna Rivasi","doi":"10.1136/ejhpharm-2024-004323","DOIUrl":"10.1136/ejhpharm-2024-004323","url":null,"abstract":"<p><p>Enfortumab vedotin (EV) is an antibody-drug conjugate (ADC) indicated for advanced or metastatic urothelial carcinoma. We describe a case of EV extravasation in a patient with metastatic bladder cancer. The extravasation area appeared swollen without clinical evidence of acute severe toxicity. Guided by the presence of monomethyl-auristatin E (MMAE) component in EV's structure, prompt management of extravasation includes the administration of a subcutaneous injection of the enzyme hyaluronidase, along with the application of warm compresses and elevation of the affected limb. Due to EV vesicant properties, special precautions should be taken in cases of extravasation. Based on the positive outcomes observed, immediate infiltration of hyaluronidase, application of a warm compress, and limb elevation are recommended. Timely recognition of extravasation and prompt initiation of treatment help to minimise the occurrence of severe complications for patients. Further comprehensive guidelines with clear instructions for managing ADC extravasation are necessary for optimal patient care.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"284-286"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unused medication among outpatients receiving cost-free medication from a community pharmacy in the Region of Southern Denmark.","authors":"Thomas Croft Buck, Mia Lolk Lund","doi":"10.1136/ejhpharm-2025-004615","DOIUrl":"10.1136/ejhpharm-2025-004615","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the extent and nature of unused medication dispensed from the hospital as cost-free medication (CFM), sent to and collected from the community pharmacy (St Thomas Pharmacy) in the Region of Southern Denmark.</p><p><strong>Methods: </strong>This observational study was conducted over 6 months. In the first 2 months, patients collecting CFM were invited to participate in an unused medication monitoring programme by completing an inclusion questionnaire. Those who consented were followed for four additional months and asked to report on unused medication during subsequent visits. Data on dispensed medication and patient-reported unused medication were collected using structured survey forms and analysed using descriptive statistics.</p><p><strong>Results: </strong>Thirteen per cent of patients reported unused medication from approximately 100 enrolled participants. Collecting CFM for themselves, the unused medication rate was 15%, compared with 8% among those collecting on behalf of others. No unused medication was reported by first-time collectors. Reported reasons included clinical changes (eg, dose adjustments, treatment discontinuation, adverse effects) and administrative errors (eg, excess quantities, incorrect formulations). The total value of unused medication was estimated at 83 000 Kr (€11 100). Extrapolated to the annual distribution volume at the St Thomas Pharmacy, the annual loss from unused medication would be 900 000 Kr (€120 000).</p><p><strong>Conclusion: </strong>The small sample size in this project is a limitation and associated with an uncertain outcome. Unused medication related to CFM is a measurable and economically significant issue, primarily driven by clinical and administrative factors. While reducing pack sizes could help mitigate unused medication, this may increase logistical burdens on patients and healthcare providers. A larger distribution model, such as dispensing through all local community pharmacies under hospital tender agreements, may offer a more efficient solution but would require legislative reform. Broader, multi-site studies are needed to validate findings and inform future policy interventions.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"219-223"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145063777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physicochemical stability of bevacizumab biosimilar CT-P16 (Vegzelma) concentrate for solution stored in original vials after first opening.","authors":"Laura Kirsch, Helen Linxweiler, Judith Thiesen, Irene Kraemer","doi":"10.1136/ejhpharm-2024-004436","DOIUrl":"10.1136/ejhpharm-2024-004436","url":null,"abstract":"<p><strong>Objective: </strong>After patent expiry of the bevacizumab originator product, several biosimilars were approved by the European Medicines Agency. In centralised preparation units, product-specific in-use stability data must be considered. Based on the available data, stability information was missing for the concentrate for solution of the bevacizumab biosimilar CT-P16 (Vegzelma, Celltrion) after first opening and prolonged storage. The aim of the study was to investigate the physicochemical stability of CT-P16 25 mg/mL concentrate for solution stored in punctured original glass vials at two different storage temperatures over a 28-day period.</p><p><strong>Methods: </strong>Three bevacizumab 25 mg/mL vials (CT-P16) were stored punctured either light protected at 2-8°C or at 25±2°C for 28 days. Samples were withdrawn on day 0, 1, 7, 14, 21, 28 and analysed by size-exclusion chromatography (SE-HPLC), ion-exchange chromatography (IE-HPLC), and dynamic light scattering (DLS). In parallel, pH values were measured and test vials visually inspected for visible particles and colour changes.</p><p><strong>Results: </strong>After the 28-day storage period, the quantitative SE-HPLC analysis indicated bevacizumab concentrations above 95% of the initial concentration in each test vial. IE-HPLC analysis revealed no signs of instability. DLS measurements showed no significant variation in the mean hydrodynamic diameter and no appearance of small-sized aggregates. The pH values of all samples remained constant, and no visible particles or colour changes were observed.</p><p><strong>Conclusion: </strong>CT-P16 25 mg/mL concentrate was found to be physicochemically stable in the original glass vial after first opening for at least 28 days when stored light protected at 2-8°C or at 25±2°C.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"266-271"},"PeriodicalIF":1.5,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}